Why Aura Biosciences, Inc.’s (AURA) Stock Is Up 5.25%
As of Tuesday, October 20, Aura Biosciences, Inc.’s AURA share price has surged by 5.25%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Aura Biosciences, Inc.’s (AURA) Stock Is Up 5.15%
As of Wednesday, October 07, Aura Biosciences, Inc.’s AURA share price has surged by 5.15%, which has investors questioning if this is right time to sell.Michael Rose
Why Aura Biosciences, Inc.’s (AURA) Stock Is Down 5.58%
As of Wednesday, September 23, Aura Biosciences, Inc.’s AURA share price has dipped by 5.58%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Aura Biosciences, Inc.’s (AURA) Stock Is Down 5.42%
As of Tuesday, September 15, Aura Biosciences, Inc.’s AURA share price has dipped by 5.42%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Aura Biosciences, Inc.’s (AURA) Stock Is Down 8.21%
As of Wednesday, August 12, Aura Biosciences, Inc.’s AURA share price has dipped by 8.21%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | AURA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $680.3 | $228.4 | 41% |
|
| Shares Out (Mil) | 94.9 | 53.9 | 61% |
|
| Institutional Ownership | 98.3% | 92.9% | 78% |
|
| Float (Mil) | 74.6 | 41.7 | 55% |
|
| Beta | 0.40 | 0.95 | 23% |
|
| Avg Daily Volume (000s) | 975 | 582 | 70% |
|
| Price Change (52-week) |
15.7% | 47.6% | 65% |
|
| Growth | AURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (36.8%) | (10.1%) | 11% |
|
| EPS (5yr) | 53.6% | 15.8% | 94 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 15.0% | (15.7%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($131) | ($44) | 9% |
|
| EPS (TTM) | ($1.773) | ($1.500) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($103) | ($33) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($40) | $2 | 22% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | $361 | $177 | 31% |
|
| Valuation | AURA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.15 | 2.19 | 57% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | AURA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (47.4%) | (47.1%) | 12% |
|
| ROE | (53.5%) | (54.1%) | 15% |
|
| Liabilities to Assets | 9.4% | 29.1% | 6% |
|
| F-Score | 4 | 2 | 33% |
|
Aura Biosciences, Inc. did not pass any screens on 10/20/2026.
